

Drug Monograph

Drug Name: **Arazlo™ (tazarotene) 0.045% lotion**
 Drug Class: **Topical Retinoid Agents**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each gram of Arazlo contains 0.45 mg (0.045%) tazarotene in a white to off-white topical lotion.

Manufacturer: Distributed by: Bausch Health US, LLC, Bridgewater, NJ 08807

Indications: Arazlo is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Costs: \$450 per 45 g tube. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Jennifer Anderson PharmD, BCPS
 Date: April 7, 2020